SCHEMBL8819205

SCHEMBL8819205

CC(C)[C@H](N)C(=O)NCC(N)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.44
DPP8 Q6V1X1 3/20 0.44
DPP9 Q86TI2 3/20 0.44
DPP7 Q9UHL4 2/20 0.44
FAP Q12884 1/20 0.44
SLC7A5 Q01650 1/20 0.41
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
PTGS2 P35354 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ECE1 P42892 2/20 0.37
METAP1 P53582 1/20 0.36
MALT1 Q9UDY8 1/20 0.35
TERT O14746 1/20 0.33
ARG1 P05089 2/20 0.33
ARG2 P78540 1/20 0.33
MME P08473 1/20 0.32
ACE P12821 1/20 0.32
CPA1 P15085 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26291258 1.00 DPP4 (0.44) DPP4DPP8DPP9DPP7FAP
SCHEMBL7199464 0.92 DPP4 (0.43) DPP4DPP8DPP9DPP7FAP
SCHEMBL7199462 0.92 DPP4 (0.43) DPP4DPP8DPP9DPP7FAP
Glycine SCHEMBL7544714 0.91 ALDH1A1 (0.40) DPP4DPP8DPP9DPP7FAP
SCHEMBL30869183 0.85 METAP1 (0.38) DPP4DPP8DPP9ALDH1A1LMNA
SCHEMBL24483749 0.83 DPP4 (0.44) DPP4DPP8DPP9DPP7FAP
Val-Gly SCHEMBL2782029 0.83 ALDH1A1 (0.57) DPP4DPP8DPP9DPP7FAP
SCHEMBL21444788 0.83 DPP4 (0.44) DPP4DPP8DPP9DPP7FAP
Val-Gly SCHEMBL2782025 0.83 ALDH1A1 (0.57) DPP4DPP8DPP9DPP7FAP
SCHEMBL27765116 0.83 DPP4 (0.44) DPP4DPP8DPP9DPP7FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129126-A1 LONG-LASTING HEPATITIS VIRUS ENTRY INHIBITOR Chengdu AODA Biotechnology Co., Ltd (CN) 2025-04-24 US disclosed
WO-2023178299-A1 PRODRUGS OF GANAXOLONE MARINUS PHARMACEUTICALS, INC. (US) 2023-09-21 WO disclosed
US-20220409734-A1 ANTIBODY DRUG CONJUGATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-12-29 US disclosed
WO-2020219287-A1 CAMPTOTHECIN DERIVATIVES IMMUNOGEN, INC. (US) 2020-10-29 WO disclosed
CN-108721599-A Therapy with HTCP Inhibitors MYR有限公司 2018-11-02 CN disclosed
EP-2780039-B1 CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER (US) 2017-11-29 EP disclosed
CN-107106686-A Combination therapy for HBV and HDV infection MYR有限公司 2017-08-29 CN disclosed
WO-2015120065-A1 GAMMA-SECRETASE INHIBITION REDUCE APOC3 LEVELS AND PLASMA TRIGLYCERIDES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2015-08-13 WO disclosed
WO-2014095773-A1 PEPTIDES AS OXYTOCIN AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2014-06-26 WO disclosed
WO-1997040078-A1 THERMOREVERSIBLE HYDROGELS COMPRISING NON-CROSSLINKED COPOLYMERS AND THEIR USE IN ELECTROPHORESIS SOANE BIOSCIENCES (US) 1997-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409734-A1 ANTIBODY DRUG CONJUGATES STING1, CGAS, TBK1 DPP4 2726/4885DPP8 2597/4885DPP9 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.